Jun 01st 2012 - Edison Investment Research today published a report on Photocure entitled "Clearing Severe Acne". In summary, the report says:
Visonac data showed a clear benefit over placebo in treating severe, inflamed acne. The pustule count fell dramatically and 43% of patients significantly improved their overall appearance. Current treatment is either old, systemic antibiotics or isotretinoin (which has major toxicities). The trial used Nedax: Photocure’s new, full-face red lamp. Photocure can now clarify its Phase III design starting H113. Acne in the US is a 40m prescription market worth $2bn; Photocure aims to sell directly.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »